QLT Inc.

218 articles about QLT Inc.

• QLT Inc. Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery System

  3/10/2010

• QLT Inc. Announces Fourth Quarter and Year End 2009 Results

  3/10/2010

• QLT Inc. Names Joseph L. Turner to the Board of Directors

  2/22/2010

• QLT Inc. Acquires Early-Stage Ophthalmic Asset for $7.5 Million

  1/4/2010

• QLT Inc. Establishes Sales Force in the United States; U.S. Subsidiary, QLT Ophthalmics, Inc. (QOI) Formed

  12/22/2009

• QLT Inc. Initiates Phase Ib Study of QLT091001 in Leber Congenital Amaurosis

  12/15/2009

• QLT Inc.: 6-Month Results From EVEREST Study Evaluating Visudyne(R) Therapy in Patients with Polypoidal Choroidal Vasculopathy

  12/9/2009

• QLT Inc. Announces MGH Litigation Settlement

  11/25/2009

• QLT Inc. Announces Share Repurchase Program

  10/27/2009

• QLT Inc. Gets Rights to Sell Visudyne in US from Novartis Pharma AG (JOBS)

  10/19/2009

• QLT Inc. (JOBS) Announces Sale of QLT USA, Inc. to TOLMAR Inc. for up to $230 Million

  10/2/2009

• QLT Inc. Announces Receipt of a CDN $45.3 Million Tax Refund

  9/8/2009

• QLT Inc. Announces Second Quarter Results for 2009

  7/28/2009

• QLT Inc. Announces Interim Data From a Phase II Clinical Trial and a Device Study for the Punctal Plug Drug Delivery System

  7/28/2009

• QLT Inc. Announces 12-month Results from Novartis Corporation Sponsored MONT BLANC Study Evaluating Standard-fluence Visudyne(R) Combination Therapy

  6/15/2009

• QLT Inc. Announces Positive Results from the Evaluation of Visudyne(R) Combination Therapy

  6/2/2009

• QLT Inc. Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court

  5/22/2009

• QLT Inc. Posts Profit; Prostate Cancer Drug Sales Help

  4/28/2009

• QLT Inc. Announces Completion of Phase Ia Safety Trial of its Synthetic Retinoid Product

  3/12/2009

• QLT Inc. Climbs to Profit on Eligard Sales

  2/19/2009